GLP-1s Beyond Weight: Bladder Benefits, Bowel Risks, and the Post-Bariatric Rescue

Overactive bladder isn't a topic most performance-oriented men spend time on, but the study is interesting because of what it implies about GLP-1 biology rather than urology specifically. Researchers used the TriNetX database to assemble a retrospective cohort of non-diabetic adults with overactive bladder who received onabotulinumtoxinA — bladder Botox — and compared those on a concurrent GLP-1 to those not. After 1:1 propensity matching on age, race, ethnicity, hypertension and BMI, they had 992 patients per arm.

The GLP-1 group had a lower incidence of urinary retention (4.9% vs. 8.6%) and urinary tract infection (8.8% vs. 13.3%), with corresponding improvements on one-year Kaplan-Meier curves. Antispasmodic initiation rates were statistically similar. The authors are careful — this is a database study, not a trial — and they frame GLP-1s as a potential adjunct worth further investigation, not a treatment. Still, the matching tried to take obesity off the table, which suggests something beyond weight loss is in play.

Roughly a quarter to a third of bariatric surgery patients regain meaningful weight or never reach their target loss in the first place. The relevant 2025 paper followed 953 patients who had bariatric surgery between 2015 and 2020; 122 of them eventually started a GLP-1 because of regain or suboptimal response. At the point of starting the drug — roughly 42 months post-op — the cohort had lost about 19% of body weight on average, and 82% had regained more than a fifth of what they'd lost.

The split between drugs was instructive. Liraglutide (the daily injection) produced a maximum additional weight loss of about 4.7%; semaglutide produced about 8.3%, with a statistically significant edge. Combined surgical and pharmacological loss reached roughly 22% on liraglutide and 26% on semaglutide. The proportion classified as suboptimal responders fell from 52% to 31%. None of this is a randomized trial — it's a single-center retrospective — but for a real-world patient population, it suggests that post-bariatric regain has a credible pharmacological off-ramp.

GLP-1s slow gastric emptying. That's part of how they work and most of why people feel full. In an otherwise healthy abdomen, the slowdown is a feature. In an abdomen that's been operated on multiple times — and that may carry adhesions stitching loops of bowel into less-than-ideal anatomy — the same slowdown becomes a plausible trigger for obstruction.

A 2025 case report describes a 59-year-old woman with an extensive abdominal surgical history who developed small bowel obstruction shortly after starting semaglutide. One case is not a rate, and the authors don't pretend otherwise. What they argue is narrow and reasonable: given the mechanism and the rising prescription volume, clinicians should think carefully before prescribing GLP-1s to patients with significant prior abdominal surgery or known adhesions. For readers in their 40s with an appendectomy scar and nothing else, this isn't the warning. For readers with multiple laparotomies behind them, it is.

The fourth piece is the most speculative and the easiest to over-read. Dermatologists reported a 14-year-old patient with congenital linear scleroderma — a rare fibrosing skin disease — whose condition had progressed despite tocilizumab, mycophenolate and methotrexate. After starting a GLP-1, the team reported improved mobility and decreased skin hardening, and speculated that anti-fibrotic and anti-inflammatory effects of GLP-1 receptor agonists could be relevant.

This is one patient. It is not evidence that GLP-1s treat scleroderma, and it would be irresponsible to imply that the same biology will redirect aging, joint stiffness, or any of the other things people are quietly hoping the drugs might do. What it does is add to a small but growing list of off-target effects that, taken together, suggest GLP-1 receptors are doing more than appetite regulation. Whether any of it survives proper trials is the question of the next five years.

The pattern across these four papers is the pattern across the whole field right now: real signals at the edges, generated by retrospective databases and individual cases, racing ahead of the randomized trials that will eventually sort signal from noise. That's not a reason to dismiss them. It is a reason to calibrate language. A propensity-matched cohort of nearly 2,000 patients is a stronger basis for hypothesis than a single case report, and both are weaker than a properly powered trial. The honest read is that GLP-1s look like a more interesting class of drugs than the weight-loss conversation has admitted, and that the list of people who should pause before starting one is also slightly longer than the marketing implies.

For the reader optimizing energy, body composition and testosterone, the practical takeaway is narrower than the headlines. The metabolic case is real. The off-target signals are interesting but not yet actionable. The risk signal in post-surgical abdomens deserves a direct conversation with a clinician who has your chart in front of them. None of this is a verdict. It's a map being drawn in real time, and the smart move is to read it as such.